Currently Viewing:
Currently Reading
Sarcopenia and Inflammation Associated With Increased Risk of Death in Patients with Colorectal Cancer
December 18, 2017 – Jaime Rosenberg
What We're Reading: State Individual Mandates; Contraceptives Rule; McCain's Cancer Treatment
December 18, 2017 – AJMC Staff
Lack of Payer Support a Barrier to Diabetes Prevention, CDC Reports
December 17, 2017 – Mary Caffrey
Researchers Discover Genetic Profile Unique to Dementia With Lewy Bodies
December 17, 2017 – Allison Inserro
Pfizer Announces Phase 3 Trial for Atopic Dermatitis Treatment
December 15, 2017 – Samantha DiGrande
Average Profit Margin on Oncology Drugs For 340B Hospitals Nears 50%
December 15, 2017 – Jaime Rosenberg
Majority of Women With Breast Cancer Surgery Did Not Feel Fully Informed of Treatment Options
December 15, 2017 – Jaime Rosenberg
AJMC® in the Press, December 15, 2017
December 15, 2017 – AJMC Staff
What We're Reading: Medicare Lab Testing; CHIP Deadline; AMA Expands Diabetes Efforts
December 15, 2017 – AJMC Staff

Fast-Acting Insulin Aspart for Mealtime Gains FDA Approval

Christina Mattina
Novo Nordisk announced that the FDA has approved its insulin aspart injection Fiasp, which can rapidly improve glycemic control at mealtimes for patients with type 1 and type 2 diabetes.
Novo Nordisk announced that the FDA has approved its insulin aspart injection Fiasp, which can rapidly improve glycemic control at mealtimes for patients with type 1 and type 2 diabetes.

According to a press release from Novo, the new injection is similar to the fast-acting insulin aspart NovoLog, but also contains niacinamide, known as vitamin B3, which helps the body absorb insulin faster. "According to an analysis in our FDA submission, Fiasp appeared in the bloodstream in 2.5 minutes. In that same analysis, NovoLog appeared in the bloodstream in 5.2 minutes. Due to its fast onset and appearance in the bloodstream, Fiasp can be dosed at the beginning of a mealtime or within 20 minutes after the start of a meal," Todd Hobbs, MD, chief medical officer for diabetes, Novo Nordisk North America.

Similar to NovoLog, Fiasp will be sold in both 10 mL vials and in prefilled delivery pens marketed as FlexTouch by Novo. It will also have an identical list price to NovoLog, and the press release indicates that it will be eligible for the manufacturer’s Savings Card and Patient Assistance Program.

While the original insulin aspart is meant to be fast-acting, the new Fiasp with the addition of niacinamide will help the drug act even more quickly. This speed is especially important during meals, which can lead to blood sugar fluctuations that make it difficult for people with both types of diabetes to achieve optimal blood glucose levels. Fiasp may be used at the start of a meal or within 20 minutes of when the patient starts eating.

The FDA approved Fiasp based on positive results from the Onset clinical trial program, which enrolled over 2000 adults with type 1 and type 2 diabetes. In phase 2a of the trial, patients with both types had a reduction in A1C levels after taking Fiasp, whether it was administered at mealtime or after they had started a meal. Trial participants reported some adverse reactions, including nasopharyngitis, upper respiratory tract infection, nausea, diarrhea, and back pain. Fiasp is not approved for children.

"With Fiasp®, we've built on the insulin aspart molecule to create a new treatment option to help patients meet their post-meal blood sugar target," said Bruce Bode, MD, FACE, president of Atlanta Diabetes Associates and associate professor at Emory University School of Medicine, in the Novo news release. "The intention of rapid acting insulin therapy is to mimic, as much as possible, the natural physiological insulin response that occurs after meals, a process that is important for optimal A1C management."

Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up

Sign In

Not a member? Sign up now!